Elitek™-rasburicase: An effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002

Leukemia

Volumn 17, Issue 3, 2003, Pages 499-514

  Navolanic, P M ^a   Pui, C H ^b   Larson, R A ^c   Bishop, M R ^d   Pearce, T E ^e   Cairo, M S ^f   Goldman, S C ^g   Jeha, S C ^h   Shanholtz, C B ⁱ   Leonard, J P ^j   McCubrey, J A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SANOFI   (France)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g Medical City Children's Hospital   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; ALLOPURINOL; ALOPRIM; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BICARBONATE; CHLORPROPAMIDE; CORTICOSTEROID; CYCLOSPORIN; DICOUMAROL; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYPOXANTHINE; IMATINIB; INTERFERON; INTERLEUKIN 2; LETROZOLE; MERCAPTOPURINE; METHOTREXATE; PURINE DERIVATIVE; RASBURICASE; RECOMBINANT ENZYME; RITUXIMAB; TAMOXIFEN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URATE OXIDASE; URIC ACID; URICOZYME; XANTHINE; XANTHINE DERIVATIVE; XANTHINE OXIDASE; ANTIMETABOLITE;

ALKALINIZATION; ASPERGILLUS FLAVUS; CANCER PATIENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DIURESIS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME PURIFICATION; EUROPE; FEVER; HUMAN; HYDRATION; HYPERURICEMIA; KIDNEY DISEASE; LEUKEMIA; LYMPHOMA; MOLECULAR CLONING; NAUSEA; NEPHROLITHIASIS; NONHUMAN; NONSENSE MUTATION; PH MEASUREMENT; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SOLUBILITY; TUMOR LYSIS SYNDROME; UNITED STATES; VOMITING; ADOLESCENT; ADULT; AGED; CASE REPORT; FEMALE; MALE; MIDDLE AGED; PRESCHOOL CHILD; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTIMETABOLITES; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; RISK FACTORS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 0037352829     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402847     Document Type: Review

References (53)

1. Pocheldy C. Hyperuricemia in leukemia and lymphoma. NY State J Med 1973; 73: 1085-1092.
2. Labovitz ED. Hyperuricemia and the kidney in the hematologic patient. In: Jepson J (ed). Hematologic Problems in Renal Disease. Menlo Park: Addison-Wesley, 1979, pp. 293-306.
3. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68: 486-491.
4. Hande KR, Hixson CV, Chabner BA. Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. J Cancer Res 1981; 41: 2273-2279.
5. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 1981; 60: 218-229.
6. Cunningham SG. Fluid and electrolyte disturbances associated with cancer and its treatment. Nurs Clin North Am 1982; 17: 579-593.
7. Boles J-M, Dutel J-L, Briere J, Mialon P, Robasckiewicz M, Garre M et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 1984; 53: 2425-2429.
8. Stapleton FB, Strother DR, Roy III S, Wyatt J, McKay CP, Murphy SB. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 1988; 82: 863-869.
9. Stokes DN. The tumour lysis syndrome: intensive care aspects of paediatric oncology. Anaesthesia 1989; 44: 133-136.
10. Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma 1992; 8: 315-318.
11. Kjellstrand CM, Campbell II DC, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med 1974; 133: 349-359.
12. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13: 273-280.
13. Chasty RC, Liu-Yin JA. Acute tumour lysis syndrome. Br J Hosp Med 1993; 49: 488-492.
14. Dietz KA, Flaherty AM. Oncologic emergencies. In: Groenwald SL, Frogge MH, Goodman M, Yarbro CH (eds). Cancer Nursing: Principles and Practice, 3rd edn. Boston: Jones & Bartlett, 1993, pp. 821-824.
15. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94: 133-139.
16. Stucky LA. Acute tumor lysis syndrome: assessment and nursing implications. Oncol Nurs Forum 1993; 20: 49-59.
17. Lawrence J. Critical care issues in the patient with hematologic malignancy. Semin Oncol Nurs 1994; 10: 198-207.
18. Veenstra J, Krediet RT, Somers R, Arisz L. Tumour lysis syndrome and acute renal failure in Burkitt's lymphoma. Description of 2 cases and a review of the literature on prevention and management. Neth J Med 1994; 45: 211-216.
19. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995; 9: 206-212.
20. Kedar A, Grow W, Neiberger RE. Clinical versus laboratory tumor lysis syndrome in children with acute leukemia. Pediatr Hematol Oncol 1995; 12: 129-134.
21. Lorigan PC, Woodings PL, Morgenstern GR, Scarffe JH. Tumour lysis syndrome, case report and review of the literature. Ann Oncol 1996; 7: 631-636.
22. Kelly KM, Lange B. Oncologic emergencies. Pediatr Clin North Am 1997; 44: 809-830.
23. Hogan DK, Rosenthal LD. Oncologic emergencies in the patient with lymphoma. Semin Oncol Nurs 1998; 14: 312-320.
24. Mahmoud HH, Leverger G, Patte C, Harvey E. Lascombes F. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998; 77(Suppl. 4): 18-20.
25. Ten Harkel ADJ, Kist-Van Holthe JE, Van Weel M, Van der Vorst MMJ. Alkalinization and the tumor lysis syndrome. Med Pediatr Oncol 1998; 31: 27-28.
26. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RAK. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999; 34: E20.
27. Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff MD, Niederhuber JE, Armitage JO, Lichter AS (eds). Clinical Oncology, 2nd edn. New York: Churchill Livingstone, 2000, pp. 750-754.
28. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27: 322-334.
29. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38: 4-8.
30. Pui C-H. Introduction-optimal treatment of malignancies associated with hyperuricemia. Semin Hematol 2001; 38(Suppl. 10): 1-3.
31. Pui C-H. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001; 38(Suppl. 10): 13-21.
32. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones - a rare complication of allopurinol therapy. N Engl J Med 1969; 280: 426-427.
33. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283: 354-357.
34. Albin A, Stephens BG, Hirata T, Wilson K, Williams HE. Nephropathy, xanthinuria, and orotic aciduria complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Metabolism 1972; 21: 771-778.
35. Shohet I, Aladjem M, Lotan D, Katznelson D, Sperling D, Kende G. Acute renal failure complicating Burkitt's lymphoma treated with chemotherapy and allopurinol. Int J Pediatr Nephrol 1980; 1: 240-241.
36. Laboureur P, Langlois C. Urate-oxydase d'Aspergillus flavus: I. Obtention, purification, propriétés. Bull Soc Chim Biol 1968; 50: 811-825.
37. Leplatois P, Le Douarin B, Loison G. High-level production of a peroxisomal enzyme: Aspergillus flavus uricase accumulates intracellularly and is active in Saccharomyces cerevisiae. Gene 1992; 122: 139-145.
38. Easton J, Noble S, Jarvis B. Rasburicase. Paediat Drugs 2001; 3: 433-437.
39. Pui CH. Rasburicase: a potent uricolytic agent. Expert Opin Pharmacother 2002; 3: 433-452.
40. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000; 18: 1758-1763.
41. Masson E, Synold TW, Relling MV, Schuetz JD, Sandlund JT, Pui CH et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 1996; 10: 56-60.
42. Pui C-H, Relling MV, Lascombes F, Harrison PL, Struxiano A, Modesir JM et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997; 11: 1813-1816.
43. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001; 97: 2998-3003.
44. Pui C-H, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19: 697-704.
45. Ducros J, Saingra S, Rampal M, Coulange C, Barbe M-C, Verzetti G. Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol 1991; 35: 89-90.
46. Bayol A, Capdevielle J, Malazzi P, Buzy A, Claude Bonnet M, Colloc'h N et al. Modification of a reactive cysteine explains differences between rasburicase and Uricozyme®, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem 2002; 36: 21-31.
47. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14: 1252-1261.
48. Atra A, Gerrard M, Hobson R, Imeson JD, Ashley S, Pinkerton CR. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) - results of the UKCCSG 9003 protocol. Br J Cancer 1998; 77: 2281-2285.
49. Patte C, Sakiroglu C, Ansoborlo S, Baruchel A, Plouvier E, Pacquement H et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol. Ann Oncol 2002;13: 789-795.
50. Pui C-H, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001; 15: 1505-1509.
51. Leverger G, Auvrignon A, LeBlanc T, Pinkerton CR, Patte C, Sonet A et al. Rasburicase, a new recombinant urate oxidase, in the treatment and prevention of hyperuricemia in patients with leukemia or lymphoma. (Submitted).
52. Crews KR, Evans WE, Pui CH, Panetta JC, Relling MV. Methotrexate pharmacokinetics following hypouricemic treatment with allopurinol vs urate oxidase in children with acute lymphoblastic leukemia. Blood 2001; 98: 113a.
53. Dann EJ, Fineman R, Rowe JM. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 354-355.